$BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

Biofrontera (BFRI) reported Q2 2026 net product revenue of $12.0 million, up 32.9% YoY. Gross margin expanded to 80% from 71%, and adjusted EBITDA loss narrowed to -$200,000. The company faces risks from an ITC exclusion order on its RhodoLED XL lamp but plans a remediation. Ameluz volume grew 30%, and the company aims for FDA approvals in 2026-2027 for new indications. Cash and cash equivalents were $4.7 million as of June 30, 2026.

Biofrontera (BFRI) reported Q2 2026 net product revenue of $12.0M, up 32.9% from $9.0M, with gross margin rising to 80% from 71%. Net loss narrowed to $0.6M from $5.3M. For six months, revenue was $22.1M (+25.4%) and gross margin 80%. A PDUFA decision for Ameluz is expected Sept. 28, 2026.

Biofrontera Inc. (BFRI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth WOBURN, Mass., August 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and comme

Biofrontera Inc. (BFRI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001858685 0001858685 2026-06-11 2026-06-11 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2026-06-11 2026-06-11 0001858685 BFRI:WarrantsToPurchaseCommonStockMember 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND

Biofrontera Inc. has announced its 2026 annual stockholders meeting, which will be held virtually on June 11, 2026. Key proposals include the re-election of two Class II directors, an amendment to increase the share limit of the 2021 Omnibus Incentive Plan from 3,750,000 to 8,750,000 shares, and the ratification of CBIZ CPAs P.C. as the independent auditor for 2026. The expanded equity plan aims to support future stock-based awards for employees, directors, and consultants, enhancing retention and hiring capabilities.

Biofrontera Inc. announced preliminary unaudited revenues for Q4 2025, expecting between $17.0 and $17.5 million, marking its highest quarterly revenue and about 35% year-over-year growth. Full-year 2025 revenues are projected to be between $41.5 and $42.0 million, an increase of 11% to 13%. The company attributes this success to strong execution, continued growth of Ameluz® PDT, and a recent pricing adjustment, with final results expected in March 2026.

Pelthos Therapeutics Inc. ( NYSE:PTHS ) on Friday acquired the U.S. commercialization rights to Xepi ( ozenoxacin ) Cream, 1%, from Biofrontera Inc. ( NASDAQ:BFRI ) and Ferrer Internacional S.A.

WOBURN, Mass., Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- Biofrontera Inc. ( Nasdaq: BFRI ) ( "Biofrontera" or the "Company" ) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy ( PDT ) , today announced the closing of its restructuring and asset ...

Woburn, MA, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Biofrontera Inc., ( Nasdaq:BFRI ) ( "Biofrontera" or the "Company" ) , a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate in a webcast presentation and host ...